Literature DB >> 16464520

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

Giuseppe Del Giudice1, Anne Katrin Hilbert, Roberto Bugarini, Ada Minutello, Olga Popova, Daniela Toneatto, Ines Schoendorf, Astrid Borkowski, Rino Rappuoli, Audino Podda.   

Abstract

To test whether inactivated influenza vaccines distributed during the 2003-2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464520     DOI: 10.1016/j.vaccine.2006.01.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

4.  [Conventional influenza vaccination compared to MF59 adjuvanted subunit vaccine].

Authors:  María Amparo Torrecilla Rojas; Miguel Pedregal González; Fermín García Rodriguez; Josefa Ruiz Fernández
Journal:  Aten Primaria       Date:  2009-10-02       Impact factor: 1.137

Review 5.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01

7.  Factors that may impact on immunosenescence: an appraisal.

Authors:  Joseph Ongrádi; Valéria Kövesdi
Journal:  Immun Ageing       Date:  2010-06-14       Impact factor: 6.400

8.  Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Michele Pellegrini; Gabriele Angiolelli; Silvia Majori; Annarosa Floreani; Marta Cecilia Busana; Chiara Bertoncello; Renzo Trivello
Journal:  Clin Dev Immunol       Date:  2010-03-29

Review 9.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

10.  MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.

Authors:  Angelika Banzhoff; Roberto Gasparini; Franco Laghi-Pasini; Tommaso Staniscia; Paolo Durando; Emanuele Montomoli; Pier Leopoldo Capecchi; Pamela Capecchi; Pamela di Giovanni; Laura Sticchi; Chiara Gentile; Anke Hilbert; Volker Brauer; Sandrine Tilman; Audino Podda
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.